These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 26412798)

  • 21. De novo DQ donor-specific antibodies are associated with worse outcomes compared to non-DQ de novo donor-specific antibodies following heart transplantation.
    Cole RT; Gandhi J; Bray RA; Gebel HM; Morris A; McCue A; Yin M; Laskar SR; Book W; Jokhadar M; Smith A; Nguyen D; Vega JD; Gupta D
    Clin Transplant; 2017 Apr; 31(4):. PubMed ID: 28181305
    [TBL] [Abstract][Full Text] [Related]  

  • 22. DQ molecules are the principal stimulators of de novo donor-specific antibodies in nonsensitized pediatric recipients receiving a first kidney transplant.
    Tagliamacco A; Cioni M; Comoli P; Ramondetta M; Brambilla C; Trivelli A; Magnasco A; Biticchi R; Fontana I; Dulbecco P; Palombo D; Klersy C; Ghiggeri GM; Ginevri F; Cardillo M; Nocera A
    Transpl Int; 2014 Jul; 27(7):667-73. PubMed ID: 24629017
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Low levels of human leukocyte antigen donor-specific antibodies detected by solid phase assay before transplantation are frequently clinically irrelevant.
    Aubert V; Venetz JP; Pantaleo G; Pascual M
    Hum Immunol; 2009 Aug; 70(8):580-3. PubMed ID: 19375474
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Impact of de novo donor-specific HLA antibodies detected by Luminex solid-phase assay after transplantation in a group of 88 consecutive living-donor renal transplantations.
    Dieplinger G; Ditt V; Arns W; Huppertz A; Kisner T; Hellmich M; Bauerfeind U; Stippel DL
    Transpl Int; 2014 Jan; 27(1):60-8. PubMed ID: 24131087
    [TBL] [Abstract][Full Text] [Related]  

  • 25. De novo donor HLA-specific antibodies predict development of bronchiolitis obliterans syndrome after lung transplantation.
    Safavi S; Robinson DR; Soresi S; Carby M; Smith JD
    J Heart Lung Transplant; 2014 Dec; 33(12):1273-81. PubMed ID: 25130554
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical and anti-HLA antibody profile of nine renal transplant recipients with failed grafts: donor-specific and non-donor-specific antibody development.
    Rebellato LM; Ozawa M; Verbanac KM; Catrou P; Haisch CE; Terasaki PI
    Clin Transpl; 2006; ():241-53. PubMed ID: 18365382
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Donor-specific HLA antibodies: risk factors and outcomes after kidney transplantation.
    Kanter Berga J; Pallardo Mateu LM; Beltran Catalan S; Puig Alcaraz N; Sancho Calabuig A; Gavela Martinez E; Avila Bernabeu A; Crespo Albiach J
    Transplant Proc; 2011; 43(6):2154-6. PubMed ID: 21839219
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Role of Donor-Specific Antibodies in Intestinal Transplantation: Experience at the University of California Los Angeles and Literature Review.
    Cheng EY; Kaneku H; Farmer DG
    Clin Transpl; 2014; ():153-9. PubMed ID: 26281140
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Deleterious Impact of Donor-Specific Anti-HLA Antibodies Toward HLA-Cw and HLA-DP in Kidney Transplantation.
    Bachelet T; Martinez C; Del Bello A; Couzi L; Kejji S; Guidicelli G; Lepreux S; Visentin J; Congy-Jolivet N; Rostaing L; Taupin JL; Kamar N; Merville P
    Transplantation; 2016 Jan; 100(1):159-66. PubMed ID: 26262501
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Association of Kidney Graft Loss With De Novo Produced Donor-Specific and Non-Donor-Specific HLA Antibodies Detected by Single Antigen Testing.
    Süsal C; Wettstein D; Döhler B; Morath C; Ruhenstroth A; Scherer S; Tran TH; Gombos P; Schemmer P; Wagner E; Fehr T; Živčić-Ćosić S; Balen S; Weimer R; Slavcev A; Bösmüller C; Norman DJ; Zeier M; Opelz G;
    Transplantation; 2015 Sep; 99(9):1976-80. PubMed ID: 25769065
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Incidences of preformed and de novo donor-specific HLA antibodies and their clinicohistological correlates in the early course of kidney transplantation.
    Huang Y; Ramon D; Luan FL; Sung R; Samaniego M
    Clin Transpl; 2012; ():247-56. PubMed ID: 23721029
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A report of the epidemiology of de novo donor-specific anti-HLA antibodies (DSA) in "low-risk" renal transplant recipients.
    Rebellato LM; Everly MJ; Haisch CE; Ozawa M; Briley KP; Parker K; Catrou PG; Bolin P; Kendrick WT; Kendrick SA; Harland RC
    Clin Transpl; 2011; ():337-40. PubMed ID: 22755428
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Late antibody-mediated rejection after heart transplantation following the development of de novo donor-specific human leukocyte antigen antibody.
    Hodges AM; Lyster H; McDermott A; Rice AJ; Smith JD; Rose ML; Banner NR
    Transplantation; 2012 Mar; 93(6):650-6. PubMed ID: 22245878
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pretransplant immunologic risk assessment of kidney transplant recipients with donor-specific anti-human leukocyte antigen antibodies.
    Marfo K; Ajaimy M; Colovai A; Kayler L; Greenstein S; Lubetzky M; Gupta A; Kamal L; de Boccardo G; Masiakos P; Kinkhabwala M; Akalin E
    Transplantation; 2014 Nov; 98(10):1082-8. PubMed ID: 24873780
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Donor specific antibodies before and after kidney transplant: the University of Colorado Experience.
    Cooper JE; Gralla J; Adebiyi O; Wiseman AC; Chan L
    Clin Transpl; 2013; ():407-12. PubMed ID: 25095536
    [TBL] [Abstract][Full Text] [Related]  

  • 36. C1q Binding Activity of De Novo Donor-specific HLA Antibodies in Renal Transplant Recipients With and Without Antibody-mediated Rejection.
    Yell M; Muth BL; Kaufman DB; Djamali A; Ellis TM
    Transplantation; 2015 Jun; 99(6):1151-5. PubMed ID: 25839705
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Low donor-to-recipient weight ratio does not negatively impact survival of pediatric heart transplant patients.
    Tang L; Du W; Delius RE; L'Ecuyer TJ; Zilberman MV
    Pediatr Transplant; 2010 Sep; 14(6):741-5. PubMed ID: 20214744
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Posttransplant soluble B-cell activating factor kinetics in pediatric recipients of first kidney allograft.
    Comoli P; Quartuccio G; Cioni M; Parodi A; Nocera A; Basso S; Fontana I; Magnasco A; Sioli V; Guido I; Klersy C; Zecca M; Cardillo M; Ghiggeri GM; Ginevri F
    Transplantation; 2015 Jan; 99(1):243-9. PubMed ID: 25033258
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Poor graft outcome in recipients with de novo donor-specific anti-HLA antibodies after living related kidney transplantation.
    Li X; Ishida H; Yamaguchi Y; Tanabe K
    Transpl Int; 2008 Dec; 21(12):1145-52. PubMed ID: 18803618
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Lack of donor and recipient age interaction in cardiac transplantation.
    Eskandary FA; Kohl M; Dunkler D; Aliabadi A; Grömmer M; Schiferer A; Gökler J; Wieselthaler G; Laufer G; Zuckermann A
    J Heart Lung Transplant; 2014 Jun; 33(6):629-35. PubMed ID: 24680281
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.